Study of Safety of RVL-1201 in Treatment of Blepharoptosis
Recruiting in Palo Alto (17 mi)
+33 other locations
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: RVL Pharmaceuticals, Inc.
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
Phase 3 study to evaluate the extended safety of RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.
Research Team
Eligibility Criteria
Inclusion Criteria
Male or Female 9 years of age or older
Females must not be pregnant or planning to get pregnant and must use acceptable form of contraception
Must be able to self-administer study medication
See 1 more
Treatment Details
Interventions
- RVL-1201 (Other)
- Vehicle ophthalmic solution (Other)
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: RVL-1201 Ophthalmic Solution, 0.1%Experimental Treatment1 Intervention
RVL-1201 (oxymetazoline hydrochloride) ophthalmic solution 0.1%
Group II: Vehicle ophthalmic solutionPlacebo Group1 Intervention
Vehicle placebo ophthalmic solution
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
CEENTACharlotte, NC
Rochester Ophthalmological GroupRochester, NY
South Shore Eye CareWantagh, NY
Cornerstone Eye CareHigh Point, NC
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
RVL Pharmaceuticals, Inc.
Lead Sponsor
Trials
10
Patients Recruited
2,400+